In 2021, Yang et al. [107] described a series of nine patients with advanced HCC and oligometastasis (less than five metastases) who were successfully downstaged after treatment with lenvatinib plus anti-PD-1 antibody and transarterial chemoembolisation. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.